New York, Jan 25, 2026, 15:31 EST — The market has closed.
- Amgen shares closed Friday 0.7% lower at $344.75, having fluctuated between $343.08 and $348.71 during the session.
- The stock is trading just under its record close and a 52-week high around $350 reached last week.
- Investors are zeroing in on the company’s Feb. 3 earnings and any fresh updates on its obesity drug candidate, MariTide.
Amgen shares ended Friday down 0.7% at $344.75, pulling back after a run that nearly took the biotech giant to record highs ahead of the weekend. About 3.8 million shares changed hands, LSEG data shows.
This matters as Amgen (AMGN.O) has turned into a popular “defensive growth” pick for certain investors—offering steady cash flows and a major potential boost from its obesity pipeline. But the upcoming catalyst could disrupt that stability.
Amgen hit its record closing price of $347.07 on January 22, with the 52-week peak slightly higher at $349.98, according to data from Macrotrends.
The obesity angle is pulling significant weight. Amgen revealed earlier this month that an extension study of its experimental obesity drug MariTide showed patients could sustain weight loss with lower or less frequent doses. CEO Bob Bradway highlighted this data at the J.P. Morgan Healthcare Conference. “While these descriptive data appear promising, we await more detailed results for further clarity,” noted BMO analyst Evan Seigerman. Meanwhile, Amgen’s R&D chief Jay Bradner insisted the company was “unambiguously in the lead” on less-frequent dosing. Reuters
Rivals aren’t standing still. Novo Nordisk’s oral Wegovy racked up 18,410 prescriptions in the U.S. during its first full week on the market, according to analysts citing IQVIA data. Investors are watching that figure closely to gauge where the weight-loss drug market is headed next. “The early oral Wegovy launch data is very strong,” said Barclays analyst James Gordon. Jefferies analyst Akash Tewari described the initial trend as “directionally encouraging” for Eli Lilly’s experimental pill, which awaits an FDA decision expected by April. Reuters
Amgen shareholders face a busy stretch ahead. MarketScreener pins the company’s fourth-quarter earnings report and conference call for Feb. 3, with the ex-dividend date following on Feb. 12.
Amgen’s board announced a $2.52 per share dividend for Q1 2026, set to be paid on March 6 to shareholders recorded by February 13, the company said in a December release.
As trading resumes Monday, all eyes will be on Amgen to see if it can maintain its footing in the mid-$340s following last week’s slide. Meanwhile, any new developments in the weight-loss sector could push the group’s momentum further.
But the setup works both ways. After a rally, the stock has less wiggle room for setbacks—whether that’s slower growth in crucial franchises or rising costs as trials scale up. Obesity programs hinge on tolerability and dosing specifics as much as the headline weight-loss results.
Investors will next focus on Feb. 3, when Amgen releases its results and may provide updates on the timeline or strategy for MariTide and its broader pipeline.
